## **FOR IMMEDIATE RELEASE**

## Amneal Introduces Ezetimibe Tablets, New Generic for Zetia®

Bridgewater, NJ (USA), June 15, 2017 - <u>Amneal Pharmaceuticals LLC</u> is pleased to announce the launch of ezetimibe tablets in 10 mg strength.

Amneal's generic, an AB-rated therapeutic equivalent to Zetia<sup>®</sup>, is available in 30-, 90- and 500-count sizes.

The product began shipping June 13<sup>th</sup> from the Amneal Kentucky distribution center and is available for purchase through major wholesalers and distributors.

Annual U.S. sales of Zetia® were nearly \$2.7 billion according to April 2017 IMS market data.

## About Amneal

Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 4,500 employees in its operations in North America, Asia, Australia and Europe, working together to bring high-quality, affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit <a href="https://www.amneal.com">www.amneal.com</a>.

All trademarks listed in this release are property of their respective owners.

###

## **CONTACTS**:

Jim Luce (sales)
Executive Vice President, Sales & Marketing
M: 949.432.1389
iim.luce@amneal.com

Cheryl Lechok (media)
President, Cheryl Lechok Communications
Dir: 203.961.9280
clechok@optonline.net

